These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 658076)

  • 1. Quantitative element investigations in urine, serum, kidney and muscle tissue of calcium oxalate stone patients.
    Matouschek E; Huber R; Schneider J; Vogg H
    Eur Urol; 1978; 4(3):206-11. PubMed ID: 658076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Citrate in urine and serum and associated variables in subgroups of urolithiasis. Results from an outpatient stone clinic.
    Schwille PO; Scholz D; Schwille K; Leutschaft R; Goldberg I; Sigel A
    Nephron; 1982; 31(3):194-202. PubMed ID: 7121665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The significance of uric acid in calcium oxalate nephrolithiasis].
    Hartung R
    MMW Munch Med Wochenschr; 1975 Mar; 117(10):387-90. PubMed ID: 804601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution to therapeutic decisions of ratios, absolute values and other measures of calcium, magnesium, urate or oxalate balance in stone formers.
    Drach GW
    J Urol; 1976 Sep; 116(3):338-40. PubMed ID: 957503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of some biochemical parameters in pyridoxine-treated calcium oxalate renal stone formers.
    Revúsová V; Gratzlová J; Zvara V; Kridl J; Suchánek B; Breza J
    Urol Int; 1977; 32(4):348-52. PubMed ID: 929778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney.
    Yagisawa T; Kobayashi C; Hayashi T; Yoshida A; Toma H
    Am J Kidney Dis; 2001 Jun; 37(6):1140-3. PubMed ID: 11382681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body size and 24-hour urine composition.
    Taylor EN; Curhan GC
    Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers.
    Otto BJ; Bozorgmehri S; Kuo J; Canales M; Bird VG; Canales B
    J Endourol; 2017 Dec; 31(12):1335-1341. PubMed ID: 29084490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renal calcium excretion and urolithiasis].
    Aruga S; Honma Y
    Clin Calcium; 2011 Oct; 21(10):1465-72. PubMed ID: 21960231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potassium citrate vs. hydrochlorothiazide to reduce urinary calcium excretion in calcium oxalate stone patients with hypercalciuria: a prospective randomized study.
    Solak V; Gökce Mİ; Yaman Ö
    Int Urol Nephrol; 2021 Sep; 53(9):1791-1796. PubMed ID: 33904027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early changes of oxalate and calcium urine excretion in those with calcium oxalate stone formation after extracorporeal shock wave lithotripsy.
    Oehlschläger S; Albrecht S; Hakenberg OW; Schrödter S; Froehner M; Manseck A; Wirth MP
    Urology; 2003 Jul; 62(1):17-21. PubMed ID: 12837412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of calcium nephrolithiasis with potassium citrate.
    Pak CY; Fuller C; Sakhaee K; Preminger GM; Britton F
    J Urol; 1985 Jul; 134(1):11-9. PubMed ID: 3892044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of allopurinol action in calcium oxalate stone formers.
    Tomlinson B; Al-Khader A; Cohen SL; Kasidas GP; Krywawych S; Edgar L; Rose GA
    Proc Eur Dial Transplant Assoc; 1981; 18():556-60. PubMed ID: 6276882
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease.
    Ahlstrand C; Tiselius HG
    J Urol; 1981 Nov; 126(5):635-9. PubMed ID: 7299925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease.
    Baggio B; Gambaro G; Favaro S; Borsatti A
    Nephron; 1983; 35(1):11-4. PubMed ID: 6888620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical factors important to calcium nephrolithiasis: evidence for impaired hydroxycarboxylic acid absorption causing hyperoxaluria.
    Cowley DM; McWhinney BC; Brown JM; Chalmers AH
    Clin Chem; 1987 Feb; 33(2 Pt 1):243-7. PubMed ID: 3802507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.